The second top selling cancer drug, Herceptin (trastuzumab) another monoclonal antibody developed by Roche. The breast cancer drug is administered via injection and works by attaching itself to HER2 receptors on cancer cells to stop them from growing. Boasting a very high survival rate, Roche is currently looking to improve efficacy further by developing combination drugs. Back in 2017, various biopharmaceutical companies were granted permission to begin making Herceptin biosimilars that are now becoming accessible in large markets worldwide. In 2018, biosimilars Tranzimera (USA) and Ontruzant (Europe) were approved, providing more access for patients to this life-saving drug.

You cannot copy content of this page